Article Title: “AI meets antibody design: Galux draws $29M series B for drug R&D”
Publication Date: February 10, 2026
On February 10, 2026, Galux, the pioneer in AI-driven antibody design, announced closing a $29 million series B round. In a significant push for innovation and application of technology in the bio-development sector, this round was led by Yuanta Investment.
The funding was intended to step up the inclusion of artificial intelligence in “rational design” of protein drug development, a field already deeply penetrated by human engineering. Galux plans to use these funds to catalyze advancements in the field of biotechnology, particularly in developing and optimizing protein therapeutics more efficiently.
Galux raising ₩42 billion ($29 million) in a series B round underscores the growing attractiveness of AI and Antibody Drug Conjugates (ADCs) to investors keen on betting on next-gen therapeutics. While we’ve seen significant recent interest in AI-driven drug discovery, the focus here on antibody design and protein therapeutics signals a particular direction for R&D investments in biotech.
Looking forward, this could lead to a paradigm shift in the market, optimizing processes and creating new opportunities for drug development. As AI starts to play more extensive roles in life sciences, it might not be surprising to see more traditional biotech investors shift gears into technologically enhanced developments certified for adaptive therapeutics.
In conclusion, the innovative fusion of AI and antibody design exhibited by Galux’s approach is reshaping the frontier of the biotech industry. As investment trends seem to be moving in this direction, it will be interesting for analysts, investors, and industry executives to ride the wave and experience these groundbreaking shifts first-hand.
On behalf of Industry Informant, we guarantee dedicated surveillance and insights from the forefront of the market, ensuring our audience stays informed and ahead of the curve. We stand committed to providing clear, factual, and analytically useful intelligence.
